Loading
Proxygen
Proxygen is a Vienna company that hunts for molecular glues, small molecules that make cells destroy cancer-driving proteins. Its two lead programmes, against p300 and CDK12, are still in the laboratory.
Overview
Proxygen is a Vienna biotechnology company founded from the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences (founders include Georg Winter and Giulio Superti-Furga) that discovers molecular glue degraders and, since April 2026, broader induced proximity therapeutics. Its most advanced programme is a first-in-class oral p300 glue degrader with sub-nanomolar potency and covalent glue pharmacology, aimed at transcription-driven cancers such as prostate, lung and bladder cancer and at CBP-mutant tumours with a synthetic lethal dependence on p300. The second lead, a brain-penetrant CDK12 glue degrader, is directed at aggressive HER2-driven cancers and tumours with central nervous system involvement. Both are preclinical, with development candidate nomination and IND-enabling studies planned over the following 12 to 18 months.
Notes
- No financing announcement or pharma collaboration terms (for example the reported Merck deals) could be fetched from the company's news pages, so funding and investors are empty. Founding year not sourced.
Connected
8Similar pages
- CompanyPrelude Therapeutics
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), PROTACs & molecular glues (targeted protein degradation).
- CompanyAmphista Therapeutics
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), PROTACs & molecular glues (targeted protein degradation), Non-small-cell lung cancer.
- CompanyFoghorn Therapeutics
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), PROTACs & molecular glues (targeted protein degradation), Prostate cancer, Non-small-cell lung cancer.
- PersonWilliam G. Nelson
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Prostate cancer.
- CompanyTreeline Biosciences
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), PROTACs & molecular glues (targeted protein degradation).
- TrialA Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), PROTACs & molecular glues (targeted protein degradation).
- IdeaEradicate dormant cancer cells: a programme to wake and kill or lock asleep disseminated cells
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Prostate cancer.
- TrialA Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Prostate cancer.
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/